Results 221 to 230 of about 2,221,794 (256)
Some of the next articles are maybe not open access.
Tipifarnib in acute myeloid leukemia
Drugs of Today, 2007Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that outcomes are improving for patients subjected to conventional intensive treatment. In addition, there is a large population of patients who are not considered fit for a more intensive treatment approach, and treatment options ...
Alan K, Burnett, Jonathan, Kell
openaire +2 more sources
Childhood Acute Myeloid Leukemia
Current Treatment Options in Oncology, 2008Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire +2 more sources
Pathophysiology of Acute Myeloid Leukemia
Acta Haematologica<b><i>Background:</i></b> Acute myeloid leukemia (AML) is a biologically heterogenous disease arising in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads to expanded proliferation of clonal myeloid progenitors and failure of differentiation, leading to fulminant AML.
Franziska, Wachter, Yana, Pikman
openaire +2 more sources
Treatment of Acute Myeloid Leukemia
2010The acute myeloid leukemias (AML) represent a heterogeneous group of malignancies derived from the pluripotent hematopoietic stem cell. These leukemias are generally characterized by genetic lesions that result in a combination of defects causing unregulated proliferation of cells and defects in cellular maturation (Gilliland and Griffin 2002).
Gibson, B +3 more
openaire +3 more sources
Immunotherapy in Acute Myeloid Leukemia
Immunotherapy, 2013Treatment of acute myeloid leukemia (AML) with current chemotherapy regimens is still disappointing, with overall survival rates of ≤ 40% at 5 years. It is now well established that AML cells can evade the immune system through multiple mechanisms, including the expression of the enzyme indoleamine 2,3 dioxygenase.
Mario, Arpinati, Antonio, Curti
openaire +2 more sources
Immunotherapy in acute myeloid leukemia
Cancer, 2015Despite the remarkable progress made in some leukemias such as CML and CLL, cytotoxic treatment for AML remains essentially unchanged over the last 4 decades. Several lines of evidence, including the graft versus leukemia effect associated with allogeneic hematopoietic stem cell transplantation (HSCT), suggest that immunotherapy is an active modality ...
Dolores A, Grosso +2 more
openaire +2 more sources
Immunotherapy for acute myeloid leukemia
Current Oncology Reports, 2005Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic ...
openaire +2 more sources
Pediatric acute myeloid leukemia [PDF]
Pediatric acute myeloid leukemia (AML) is currently associated with survival rates as high as 70%. However, many events still occur, side effects are significant, and late effects occur and can even be life-threatening. Thus, the treatment of pediatric AML still needs further improvement.
openaire +4 more sources
New England Journal of Medicine, 1999
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Inqovi for Acute Myeloid Leukemia
The Medical Letter on Drugs and TherapeuticsThe FDA has approved Inqovi (Taiho Oncology), a fixed-dose combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine, for use in combination with venetoclax (Venclexta, and generics) for oral treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are ≥75 years old or who have ...
openaire +2 more sources

